Zevra Therapeutics
Tracked across 3 events · 41 articles · First seen Jun 08, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Zevra Therapeutics has strengthened its intellectual property protection for MIPLYFFA by submitting a new patent for Orange Book listing, extending its exclusivity until 2041. This action aims to maximize the long-term value of the drug and support patients with Niemann-Pick disease type C.
Jun 08, 2026 · 6 articles
Regulatory
Impact: Zevra Therapeutics is the central entity, facing a 24% stock drop and a securities investigation following the CHMP's negative opinion on its lead drug arimoclomol. The company plans to request a re-examination and continues its Expanded Access Program.
Jul 24, 2026 · 29 articles
Business
Impact: Commercial product MIPLYFFA included in acquired portfolio.
Jul 14, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Zevra Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard